Patient involvement in health policy is a patchwork across the EU. Putting the lived experience front and centre of policy-making was prioritised at a recent high-level policy event organised by the ...

About AVT23 AVT23 is a monoclonal antibody and proposed biosimilar to Xolair ® (omalizumab). AVT23 is an investigational compound and has not received regulatory approval in any country. Biosimilarity ...

China's virtual monopoly on the supply of many APIs could be dangerous for the security of medicine supply to Western ...

CHMP upheld earlier opinions that Translarna is not of significant benefit to DMD due to nonsense mutations; European ...

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has once again snubbed Translarna (ataluren), PTC Therapeutics’ treatment for the genetic disease Duchenne ...

Astellas to withdraw European marketing authorization application for avacincaptad pegol to treat GA secondary to AMD: Tokyo Tuesday, October 29, 2024, 13:00 Hrs [IST] Astellas Ph ...

Directive Might Cause Massive Medicine Shortages Affecting Millions Of Patients Across Europe ...

Bayer seeks European approval for darolutamide in combo with ADT in patients with metastatic hormone-sensitive prostate cancer: Berlin Wednesday, October 16, 2024, 13:00 Hrs [IST] ...

Vutrisiran treatment leads to a decrease in serum vitamin A levels. Supplementation of approximately, but not exceeding, 2500 IU to 3000 IU vitamin A per day is advised for patients taking vutrisiran.

The Canadian healthcare-focused royalty company said Monday that the royalty interest in the worldwide net sales of all formulations of sebetralstat from KalVista Pharmaceuticals was acquired for an ...

Homeopaths claim that substances that can cause symptoms when given to generally healthy people can be used in tiny doses to ...

A European-style pharmaceutical regulatory body will be created in Ukraine.Deputy Health Minister Maryna Slobodnichenko said ...